Testing SNA014 for Pancreatic Cancer
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This early-stage trial tests a new drug called SNA014 for pancreatic cancer. The drug targets a specific protein marker (Claudin-18.2) on cancer cells, and researchers want to see if it's safe and effective for patients whose tumors have this marker.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old
- You have been diagnosed with pancreatic cancer and your tumor can be tested for a specific protein marker called Claudin-18.2
- You have recent imaging scans (CT, MRI, PET-CT, or endoscopy) from the last month, or pathology test results from the last year
- You do not have other active cancers
- You do not have severe uncontrolled infections or serious medical conditions that would make participation unsafe
- You have a life expectancy of more than 3 months
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial uses a special PET scan to see if a new imaging agent can find a protein called claudin 18.2 on cancer cells in pancreatic, stomach, or gastroesophageal junction cancers. The scan may help doctors better see the cancer and guide treatment decisions.
This trial uses a special PET scan (68Ga-grazytracer) to see how well immunotherapy is working for pancreatic cancer. It may help your doctor understand if your treatment is effective.
This study tests a new imaging agent that may help see certain cancers (colorectal, gastric, or pancreatic) more clearly on PET scans. It may help doctors better understand your tumor and guide treatment decisions.
This study tests a radioactive drug that targets a protein called Claudin 18.2 found on some stomach and pancreatic cancer cells. Researchers will track where the drug goes in your body and how it exits, to see if it's a safe and effective way to deliver radiation directly to tumors.
This trial tests a new drug called ANO31905 added to standard chemotherapy for people with advanced pancreatic cancer that has a specific protein called CLDN18.2 on its cells. The study aims to see if the combination works better than chemo alone.
This study uses small pancreatic cancer samples grown in the lab to understand which treatments may work best for people with pancreatic cancer. It may help researchers better “profile” tumors so standard care can be matched to the most effective options.
Hear when a new Pancreatic cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.